Lastly, although a sublethal concentration of doxorubicin promotes osteosarcoma cell migration, combining this treatment with CHK/MATK overexpression in osteosarcoma cells hinders, or at least partially attenuates, cell migration. Here, MATK is linked to osteosarcoma.